Fluorocopolymer-coated nitinol self-expanding paclitaxeleluting stent: Pharmacokinetics and vascular biology responses in a porcine iliofemoral model

EuroIntervention

Volumn 12, Issue 6, 2016, Pages 790-797

  Hou, Dongming ^a   Huibregtse, Barbara A ^a   Eppihimer, Michael ^a   Stoffregen, William ^a   Kocur, Gordon ^a   Hitzman, Cory ^a   Stejskal, Elizabeth ^a   Heil, John ^a   Dawkins, Keith D ^a  

^a BOSTON SCIENTIFIC CORPORATION   (United States)

Author keywords

Fluorocopolymer; Paclitaxel; Self expanding nitinol stent

Indexed keywords

COPOLYMER; FLUOROCOPOLYMER; PACLITAXEL; UNCLASSIFIED DRUG; ALLOY; ANTINEOPLASTIC AGENT; NITINOL; POLYMER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOGRAPHY; ARTICLE; BARE METAL STENT; BLOOD VESSEL REACTIVITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DRUG RESPONSE; FEMORAL ARTERY; FEMORAL ARTERY STENT; FOLLOW UP; HUMAN; HUMAN CELL; ILEOFEMORAL ARTERY; IN VITRO STUDY; MATERIAL COATING; MAXIMUM PLASMA CONCENTRATION; MIGRATION INHIBITION; MORPHOMETRICS; NONHUMAN; PIG; SELF EXPANDING NITINOL STENT; ANIMAL; ANIMAL MODEL; CELL MOTION; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG EFFECTS; DRUG ELUTING STENT; EVALUATION STUDY; NEOINTIMA; SMOOTH MUSCLE CELL;

ALLOYS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL MOVEMENT; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMORAL ARTERY; HUMANS; MODELS, ANIMAL; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PACLITAXEL; POLYMERS; SWINE;

EID: 84983050347     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV12I6A128     Document Type: Article

References (24)

1. Sarode K, Spelber DA, Bhatt DL, Mohammad A, Prasad A, Brilakis ES, Banerjee S. Drug delivering technology for endovascular management of infrainguinal peripheral artery disease. JACC Cardiovasc Interv. 2014;7:827-39.
2. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR; RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-76.
3. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-88.
4. Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G; VIVA Physicians, Inc. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910-9.
5. Bosiers M, Torsello G, Gissler HM, Ruef J, Müller-Hulsbeck S, Jahnke T, Peeters P, Daenens K, Lammer J, Schroe H, Mathias K, Koppensteiner R, Vermassen F, Scheinert D. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16:261-9.
6. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-48.
7. Marroquin OC, Selzer F, Mulukutla SR, Williams DO, Vlachos HA, Wilensky RL, Tanguay JF, Holper EM, Abbott JD, Lee JS, Smith C, Anderson WD, Kelsey SF, Kip KE. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342-52.
8. Zeller T, Dake MD, Tepe G, Brechtel K, Noory E, Beschorner U, Kultgen PL, Rastan A. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6:274-81.
9. Dake MD, Van Alstine WG, Zhou Q, Ragheb AO. Polymerfree paclitaxel-coated Zilver PTX Stents-evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol. 2011;22:603-10.
10. Tomoi Y, Kuramitsu S, Soga Y, Aihara H, Ando K, Nobuyoshi M. Vascular response after Zilver PTX stent implantation for superficial femoral artery lesions: serial optical coherence tomography findings at 6 and 12 months. J Endovasc Ther. 2015;22:41-7.
11. Ishihara T, Iida O, Awata M, Shiraki T, Nanto S, Uematsu M. Angioscopically apparent large thrombus and uncovered stent struts 6 months after late stent thrombosis of a paclitaxel-coated nitinol drug-eluting stent implanted in the superficial femoral artery. Cardiovasc Interv Ther. 2014;29:82-5.
12. Pedrini L, Dondi M, Magagnoli A, Magnoni F, Pisano E, Del Giudice E, Santoro M. Evaluation of thrombogenicity of fluoropassivated polyester patches following carotid endarterectomy. Ann Vasc Surg. 2001;15:679-83.
13. Hasebe T, Shimada A, Suzuki T, Matsuoka Y, Saito T, Yohena S, Kamijo A, Shiraga N, Higuchi M, Kimura K, Yoshimura H, Kuribayashi S. Fluorinated diamond-like carbon as antithrombogenic coating for blood-contacting devices. J Biomed Mater Res A. 2006;76:86-94.
14. Chinn JA, Sauter JA, Phillips RE Jr, Kao WJ, Anderson JM, Hanson SR, Ashton TR. Blood and tissue compatibility of modified polyester: thrombosis, inflammation, and healing. J Biomed Mater Res. 1998;39:130-40.
15. Chin-Quee SL, Hsu SH, Nguyen-Ehrenreich KL, Tai JT, Abraham GM, Pacetti SD, Chan YF, Nakazawa G, Kolodgie FD, Virmani R, Ding NN, Coleman LA. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. Biomaterials. 2010;31:648-57.
16. Pendyala LK, Li J, Shinke T, Geva S, Yin X, Chen JP, King SB 3rd, Robinson KA, Chronos NA, Hou D. Endotheliumdependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. JACC Cardiovasc Interv. 2009;2:253-62.
17. Axel Di, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Köveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-45.
18. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets. 2003;3:193-203.
19. Kamath KR, Barry JJ, Miller KM. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev. 2006;58:412-36.
20. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ, Scott DS, Froehlich J, Virmani R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104:473-9.
21. Rogers CD. Drug-eluting stents: clinical perspectives on drug and design differences. Rev Cardiovasc Med. 2005;6 Suppl 1: S3-12.
22. Müller-Hülsbeck S, Keirse K, Zeller T, Schroë H, Diaz-Cartelle J. Twelve Month Results from the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease. J Endovasc Ther. 2016 May 18. [Epub ahead of print].
23. Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS, Dangas GD. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011;58:1569-77.
24. Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J. 2011;75:1287-96.